论文部分内容阅读
目的探讨核因子κB p65(NF-κB p65)表达与卵巢癌化疗耐药的关系。方法收集中国医科大学附属盛京医院2006—2012年符合纳入条件并完善随访的原发性上皮性卵巢癌患者176例,敏感组101例,耐药组75例。采用免疫组化法测定两组中NF-κB p65的表达情况,探讨其表达与卵巢癌化疗耐药的关系。结果 NF-κB p65在敏感组的表达程度明显低于耐药组(P<0.05)。卵巢癌的病理分期、淋巴结转移和NF-κB p65的表达均为耐药性相关的独立危险因素(P均<0.05)。病理分期、NF-κB p65的表达均为卵巢癌预后独立危险因素(P均<0.05)。结论 NF-κB p65的高度表达是卵巢癌患者化疗耐药的高危因素。
Objective To investigate the relationship between the expression of nuclear factor κB p65 (NF-κB p65) and chemoresistance in ovarian cancer. Methods A total of 176 patients with primary epithelial ovarian cancer who met the inclusion criteria and were followed up were included in Shengjing Hospital affiliated to China Medical University from 2006 to 2012, 101 in sensitive group and 75 in resistant group. The expression of NF-κB p65 in the two groups was detected by immunohistochemistry, and the relationship between the expression of NF-κB p65 and chemoresistance in ovarian cancer was analyzed. Results The expression of NF-κB p65 in the sensitive group was significantly lower than that in the drug-resistant group (P <0.05). The pathological staging of ovarian cancer, lymph node metastasis and the expression of NF-κB p65 were independent risk factors related to drug resistance (all P <0.05). The pathological stage and the expression of NF-κB p65 were independent risk factors for prognosis of ovarian cancer (all P <0.05). Conclusion The high expression of NF-κB p65 is a risk factor for chemoresistance in patients with ovarian cancer.